Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORION-16 inclisiran trial in adolescents with heterozygous familial hypercholesterolemia
MOH_2021-02-28_009791Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2021
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heterozygous familial hypercholesterolemia (HeFH) comparing Inclisiran then open-label inclisiran with Placebo then open-label inclisiran (2 arms). Primary endpoint: Percent change in LDL-C at Day 330. Started Jan 2021; status: active, not recruiting.
02
Drugs
inclisiran
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on MOH_2021-02-28_009791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-02-28_009791.